Condition: Gastroesophageal Reflux Disease (GERD) · Sponsor: Implantica CE Reflux Ltd.
This post-market registry aims to assess safety and performance of RefluxStop™ in the treatment of Gastroesophageal Reflux Disease (GERD) in standard of care procedures.
This description comes directly from the study's public registry record.
Souheila Moutiq · +41 78 249 77 28 · souheila.moutiq@implantica.com
Always discuss trial participation with your own doctor first.
| Klinikum Friedrichshafen GmbH | Friedrichshafen, Germany | Active Not Recruiting |
| Ospedale IRCCS Saverio De Bellis | Bari, Italy | Recruiting |
| Ospedale Buon Consiglio Fatebenefratelli | Naples, Italy | Recruiting |
| Akershus Universitetssykehus HF | Lørenskog, Norway | Recruiting |
| Inselspital, Universitätsspital Bern | Bern, Switzerland | Recruiting |
| Hirslanden Klinik | Bern, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05870163